Mavacamten (CAMZYOS), as an emerging myocardial myosin inhibitor, has shown significant efficacy in the treatment of obstructive hypertrophic cardiomyopathy (HCM). However, when using this medication, patients need to be aware of some important precautions to ensure its effectiveness.

Precautions for Mavacamten (CAMZYOS)

Heart Failure

Mavacamten can reduce cardiac contraction and cause heart failure or complete blockage of ventricular function in patients. Patients with severe concurrent diseases (such as severe infections) or arrhythmias (such as atrial fibrillation or other uncontrolled rapid arrhythmias) are at a higher risk of developing systolic dysfunction and heart failure. Assess the patient's clinical status and LVEF regularly before and during treatment, and adjust the dose of mavacamten accordingly.

Heart Failure or Loss of Efficacy Due to CYP450 Drug Interactions

Mavacamten is mainly metabolized by CYP2C19 and CYP3A4 enzymes. Concomitant use of mavacamten with drugs that interact with these enzymes may lead to life-threatening drug interactions in patients, such as heart failure or loss of efficacy.

Patients need to be informed of potential drug interactions, including those with over-the-counter drugs (such as omeprazole, esomeprazole, or cimetidine). It is recommended that patients inform their healthcare providers of all concomitant products before and during treatment with mavacamten.

Mavacamten REMS Program

Due to the risk of heart failure caused by systolic dysfunction, mavacamten is only available through a restricted program called the Mavacamten REMS Program. The key requirements of the Mavacamten REMS Program include:

Prescribing physicians must be certified by participating in the Mavacamten REMS Program.

Patients must enroll in the Mavacamten REMS Program and comply with ongoing monitoring requirements.

Pharmacies must be certified by registering with the Mavacamten REMS Program and must only dispense to patients authorized to receive mavacamten.

Wholesalers and distributors may only distribute to certified pharmacies.

Embryo-Fetal Toxicity

Taking this product may cause fetal toxicity. Before treatment, confirm that women of reproductive potential are not pregnant, and advise patients to use effective contraceptive measures during treatment with mavacamten and for 4 months after the last dose.

Inform women of reproductive potential of the potential risk to the fetus if pregnant women are exposed to mavacamten during pregnancy.